Walpole: Trials.ai cuts study design time from 9–12 months to weeks
Kim Walpole · 1315 Her Best Friend Died From Terminal Cancer, She Launches MedTech SaaS Raising $2.5m on $10m Pre · Mar 1, 2019 · at 4:01
Kim Walpole, founder and CEO of Trials.ai, discusses how her AI platform accelerates clinical trial timelines compared to traditional pharmaceutical methods.
0:00 / 0:07exact quote · 7.1s
720p mp4 · rendered on demand · StarZero watermark
“On the study design side, you know, it takes anywhere from nine to 12 months to do that. We're cutting that down to weeks and eventually days.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Kim Walpole
Kim Walpole: Trials.ai in fundraising talks at $10M pre-money valuation
“We're conversations we're having is at a ten million pre.”
Walpole: Average phase two trial generates about $200K annually for Trials.ai
“For us, an average trial, maybe a phase two trial of 350 users would generate about 200 K on average annually.”
Walpole: Trials.ai raised $750k in December and is raising $2.5M
“And we raised 750,000 back in the end of December, and now we're doing a 2.5 million dollar raise.”